Author:
Tegegn Dereje Fedasa,Belachew Habtamu Zewude,Salau Ayodeji Olalekan
Abstract
AbstractChronic hepatitis B remains a worldwide health concern. Presently, many drugs, such as Clevudine and Telbivudine, are recommended for the treatment of chronic hepatitis B disease. For this purpose, the quantum chemical analysis of ELUMO-HOMO (Egap), ionization potential (IP), electron affinity (EA), electronegativity (EN), chemical hardness (η), chemical potential (μ), chemical softness (S), electrophilicity index (ω), electron accepting capability (ω+), electron-donating capability (ω-), Nucleophilicity index (N), additional electronic charge (∆Nmax), Optical softness (σ0) and Dipole Moment, IR and UV–Vis spectra, molecular electrostatic potential (MEP) profile, Mulliken charge analysis, natural bond orbital (NBO) were examined in this study. The dipole moment of the compounds suggests their binding pose and predicted binding affinity. The electrophilic and nucleophilic regions were identified, and techniques such as NBO, UV–Vis, and IR were used to gain insights into the molecular structure, electronic transitions, and potential drug design for Hepatitis B treatment. Calculations for this study were carried out using the Gaussian 09 program package coupled with the DFT/TDDFT technique. The hybrid B3LYP functional method and the 6-311++G(d, p) basis set were used for the calculations.
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Semvua, B. K., Daniel, W. G., Bonaventura, C. T., Mpondo, F. A. B. & Hyasinta, J. Hepatitis B virus infection in Tanzania: Current status and challenges. J. Trop. Med. 2018, 1–10 (2018).
2. Kafeero, H. M. et al. Prevalence and predictors of hepatitis B virus (HBV) infection in East Africa: Evidence from a systematic review and meta-analysis of epidemiological studies published from 2005 to 2020. Arch. Public Health 79(167), 1–19 (2021).
3. WHO. Global Hepatitis Report. Available online: https://www.who.int/publications-detail-redirect/9789241565455 (France, Geneva, 2017).
4. Noonan, T. J., Mzondo, B., Bourne, S. A. & Caira, M. R. Polymorphism of the antiviral agent clevudine. R. Soc. Chem. 18, 8172 (2016).
5. Osborn, M. K. Safety and efficacy of telbivudine for the treatment of chronic hepatitis B. Ther. Clin. Risk Manag. 5, 789–798 (2009).